GlassScriptPhysician profile
Amanda Nicole Szeltner
NPI 1114403490
$2,949.54
in general payments reported to CMS, 2019-2025
16 companies · $678 in 2025
The $678 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $389 · 2022: $645 · 2023: $543 · 2024: $695 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.49 |
| Education | $194.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $595.11 | 2021-2025 | Niktimvo, Jakafi |
| Kite Pharma, INC. | $583.94 | 2022-2025 | Yescarta |
| Janssen Biotech, INC. | $378.66 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $339.52 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $146.17 | 2022-2023 | Darzalex, Tecvayli |
| Adc Therapeutics America, INC. | $128.72 | 2022 | |
| Jazz Pharmaceuticals INC. | $124.47 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $123.01 | 2022 | |
| Legend Biotech USA INC. | $121.55 | 2023-2024 | Carvykti |
| Celgene Corporation | $107.69 | 2024-2025 | Breyanzi |
| Shionogi INC | $93.73 | 2023 | Fetroja |
| Ipsen Biopharmaceuticals, INC | $76.65 | 2023 | Tazverik |
| Genmab U.S., INC. | $58.35 | 2024 | Epkinly |
| Novartis Pharmaceuticals Corporation | $33.67 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.85 | 2025 | Ninlaro |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Bct, INC. | $14.45 | 2025 | Spectra Optia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Szeltner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.